Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

This publication has 48 references indexed in Scilit:

• Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial
  The Lancet, 2010
• Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
  New England Journal of Medicine, 2009
• Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
  New England Journal of Medicine, 2008
• Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial
  The Lancet, 2008
• Low LDL-C Levels and Cancer
  Journal of the American College of Cardiology, 2008
• Rosuvastatin in Older Patients with Systolic Heart Failure
  New England Journal of Medicine, 2007
• Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)
  JAMA, 2002
• Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
  New England Journal of Medicine, 1998
• Benefits and Risks of HMG-CoA Reductase Inhibitors in the Prevention of Coronary Heart Disease A Reappraisal
  Drug Safety, 1996
• Serum Cholesterol Levels and Six-Year Mortality from Stroke in 350,977 Men Screened for the Multiple Risk Factor Intervention Trial
  New England Journal of Medicine, 1989